Skip to content

OSR HEALTH, INC.: 10-K filed 2025-04-22

What OSR HEALTH, INC. reported in its annual report filed 2025-04-22 (fiscal FY 2024): 28 published measures, 55 facts as tagged in accession 0001213900-25-034116.

This filing

Form
10-K (annual report)
Filed
2025-04-22
Fiscal period
fiscal FY 2024
Accession
0001213900-25-034116 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All OSR HEALTH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-12-312,303,041USD
At 2023-12-3136,627,733USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-12-318,788,809USD
At 2023-12-314,108,272USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-12-31-8,333,411USD
At 2023-12-31-3,906,792USD
At 2022-12-31-37,508USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-12-3166,135USD
At 2023-12-3115,419USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-2,410,879USD366
2023-01-01 to 2023-12-31403,780USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-2,187,946USD366
2023-01-01 to 2023-12-31-818,766USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-33,669,029USD366
2023-01-01 to 2023-12-3134,539,499USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-12-3135,907,691USD366
2023-01-01 to 2023-12-31-33,829,815USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-12-31-8,333,627USD
At 2023-12-31-3,907,008USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-12-314,481,692shares366
2023-01-01 to 2023-12-317,688,260shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-12-314,481,692shares366
2023-01-01 to 2023-12-317,719,699shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-0.54USD/shares366
2023-01-01 to 2023-12-310.05USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-0.54USD/shares366
2023-01-01 to 2023-12-310.05USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-01-01 to 2024-12-31295,728USD366
2023-01-01 to 2023-12-31540,811USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-3,524,549USD366
2023-01-01 to 2023-12-31-1,830,700USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-12-31455,398USD
At 2023-12-3122,627USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-12-316,718,809USD
At 2023-12-312,038,272USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2024-01-01 to 2024-12-3136,232,029USD366
2023-01-01 to 2023-12-3135,995,728USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-12-312,155,000shares
At 2023-12-312,155,000shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-12-3166,135USD
At 2023-12-3115,419USD
At 2022-12-31124,501USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-2,115,151USD366
2023-01-01 to 2023-12-31944,591USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-12-313,524,549USD366
2023-01-01 to 2023-12-311,830,700USD365

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-01-01 to 2024-12-3143,011USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-01-01 to 2024-12-311,409,398USD366
2023-01-01 to 2023-12-312,775,291USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2024-01-01 to 2024-12-31295,728USD366
2023-01-01 to 2023-12-31540,811USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2024-01-01 to 2024-12-31739,910USD366
2023-01-01 to 2023-12-31342,447USD365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-461,957USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-12-319,157,500USD365

Inspect the source

Entity
OSR HEALTH, INC. / CIK 0001840425
Captured
2026-09-21T17:37:27.107Z
SEC response SHA-256
a0d30433e6a20a35440697935a5f38c30b52570c7afa4a92b7b1c23550f84d90

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001840425.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))